206 care center directors sign a letter citing clinical consequences if decision moves forward.
The physical footprint of the Cystic Fibrosis Foundation Therapeutics Lab grew by about a third this year, enabling startup companies and industry scientists to work and learn alongside lab staff.
|
4 min read
The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.
|
2 min read
Vertex’s copay assistance changes add an undue burden for people living with an already expensive, challenging lifelong disease.
|
3 min read
Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.
|
3 min read
Results show that people on Trikafta® enrolled in the six-week study were able to safely stop taking one of the two common CF medications without negatively affecting their health.
|
4 min read
The Cystic Fibrosis Foundation is providing up to $5 million to develop a method to deliver a healthy copy of the CFTR gene into the lung cells of people with CF that is unlikely to trigger an immune system response.
|
4 min read
Addressing variability in newborn screening can prevent missed diagnoses and delays in early care intervention.
|
3 min read
Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.
|
3 min read
CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
|
3 min read